keyword
https://read.qxmd.com/read/38646274/long-term-survival-of-a-patient-with-anaplastic-thyroid-carcinoma-treated-with-hypofractionated-radiotherapy-a-case-report
#1
Mitsuki Tanaka, Yoshiomi Hatayama, Hideo Kawaguchi, Ichitaro Fujioka, Masahiro Aoki
Anaplastic thyroid carcinoma, a rare type of primary thyroid cancer, is one of the most aggressive neoplasms with a poor prognosis. Many cases are in the advanced stage at the time of the initial visit, and curative treatment is impossible. Because of the highly radioresistant nature of anaplastic thyroid carcinoma, this condition cannot be properly controlled with conventional radiotherapy. Herein, we report the case of a patient with anaplastic thyroid carcinoma who underwent hypofractionated radiotherapy, attained a complete response, and is still alive more than 10 years after treatment with no evidence of disease...
March 2024: Curēus
https://read.qxmd.com/read/38631536/efficacy-and-toxicity-of-moderately-hypofractionated-radiotherapy-with-helical-tomotherapy-versus-conventional-radiotherapy-in-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer-receiving-concurrent-chemotherapy-a-multicentre-randomized-phase-iii
#2
REVIEW
Qi Zhang, Shaonan Fan, Xiaohong Xu, Shisuo Du, Guangying Zhu, Chaoyang Jiang, Shi-An Xia, Qiwen Li, Qifeng Wang, Dong Qian, Ming Zhang, Han Xiao, Gang Chen, Zhaochong Zeng, Jian He
PURPOSE: The standard treatment schedule for unresectable stage III non-small-cell lung cancer (NSCLC) is chemotherapy with concurrent radiotherapy (60 Gy delivered in 30 fractions), although moderately hypofractionated radiotherapy (Hypo-RT) has also been considered as an alternative strategy. This study aimed to compare the efficacy and toxicity of moderately Hypo-RT with helical TomoTherapy versus conventionally fractionated radiotherapy (Con-RT) in patients with unresectable stage III NSCLC receiving concurrent chemotherapy...
April 15, 2024: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/38630954/phase-ii-single-arm-trial-of-induction-and-concurrent-vismodegib-with-curative-intent-radiation-therapy-for-locally-advanced-unresectable-basal-cell-carcinoma
#3
JOURNAL ARTICLE
Christopher A Barker, Suzanne Dufault, Sarah T Arron, Alan L Ho, Alain P Algazi, Lara A Dunn, Audrey A Humphries, Carter Hultman, Ming Lian, P Daniel Knott, Sue S Yom
PURPOSE: Locally advanced, unresectable basal cell carcinoma (LA BCC) can be treated with radiation therapy (RT), but locoregional control (LRC) rates are unsatisfactory. Vismodegib is a hedgehog pathway inhibitor (HPI) active in BCC that may radiosensitize BCC. We evaluated the combination of vismodegib and RT for patients with LA BCC. METHODS: In this multicenter, single-arm, phase II study, patients with unresectable LA BCC received 12 weeks of induction vismodegib, followed by 7 weeks of concurrent vismodegib and RT...
April 17, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38618919/clinical-manifestation-risk-factors-and-immune-checkpoint-inhibitor-rechallenge-of-checkpoint-inhibitor-associated-pneumonitis-in-patients-with-lung-cancer
#4
JOURNAL ARTICLE
Xuemeng Li, Fang Yang, Baogang Liu, Leiguang Ye, Jingwen Du, Xiaona Fan, Yue Yu, Mengwei Li, Li Bu, Zhuoqi Zhang, Lili Xie, Wuquan Li, Jiaqing Qi
Immune-related adverse effects can lead to damage to various systems of the body, checkpoint inhibitor-associated pneumonitis (CIP) is one of the potentially lethal immune-related adverse effects. However, evidence regarding the risk factors associated with CIP is limited. To timely and accurate identification and prompt treatment of CIP, understanding the risk factors for multimorbidity among diverse study populations becomes crucial. We retrospectively analyzed the clinical data of 1131 patients with lung cancer receiving immunotherapy to identify 110 patients with CIP, the clinical characteristics and radiographic features of patients with CIP were analyzed...
April 15, 2024: Journal of Immunotherapy
https://read.qxmd.com/read/38617757/clinical-radiomics-nomogram-for-the-risk-prediction-of-esophageal-fistula-in-patients-with-esophageal-squamous-cell-carcinoma-treated-with-intensity-modulated-radiation-therapy-or-volumetric-modulated-arc-therapy
#5
JOURNAL ARTICLE
Zhaohui Li, Jie Gong, Liu Shi, Jie Li, Zhi Yang, Guangjin Chai, Bo Lv, Geng Xiang, Bin Wang, Shamus R Carr, Alfonso Fiorelli, Mei Shi, Yilin Zhao, Lina Zhao
BACKGROUND: Esophageal fistula (EF) is a serious adverse event as a result of radiotherapy in patients with esophageal cancer (EC). We aimed to identify the predictive factors and establish a prediction model of EF in patients with esophageal squamous cell carcinoma (ESCC) who underwent intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT). METHODS: Patients with ESCC treated with IMRT or VMAT from January 2013 to December 2020 at Xijing Hospital were retrospectively analyzed...
March 29, 2024: Journal of Thoracic Disease
https://read.qxmd.com/read/38615197/multicenter-evaluation-of-the-safety-and-efficacy-of-selective-internal-radiation-therapy-with-yttrium-90-resin-microspheres-in-taiwan-data-from-the-resin-registry
#6
JOURNAL ARTICLE
Rheun-Chuan Lee, Po-Chin Liang, Huei-Lung Liang, Yung-Fang Chen, Chun-Yen Yu, Pin-Nan Cheng, Chien-Fu Hung, Cheng-Yuan Hsia, Hsueh-Chou Lai, Ming-Chih Ho, Yu-Fan Cheng, Yi-Sheng Liu, Yee Chao, Chien-Hung Chen
BACKGROUND AND AIM: The REgistry of Selective Internal radiation therapy in AsiaNs (RESIN) was a multicenter, single-arm, prospective, observational study of 90 Y resin microspheres in patients with hepatocellular carcinoma (HCC) or metastatic colorectal cancer (mCRC) from Taiwan. RESIN is the first real-life clinical study of this therapy in an Asian cohort. Study objectives were to evaluate the safety and efficacy of 90 Y resin microspheres. METHODS: Adults with HCC or mCRC scheduled to receive SIRT with 90 Y resin microspheres were included...
April 13, 2024: Journal of Gastroenterology and Hepatology
https://read.qxmd.com/read/38614284/long-term-survival-outcomes-and-quality-of-life-of-image-guided-proton-therapy-for-operable-stage-i-non-small-cell-lung-cancer-a-phase-2-study
#7
JOURNAL ARTICLE
Koichiro Nakajima, Masanosuke Oguri, Hiromitsu Iwata, Yukiko Hattori, Shingo Hashimoto, Kento Nomura, Kensuke Hayashi, Toshiyuki Toshito, Kenji Akita, Fumiya Baba, Hiroyuki Ogino, Akio Hiwatashi
BACKGROUND AND PURPOSE: This study evaluated long-term efficacy, safety, and changes in quality of life (QOL) of patients after image-guided proton therapy (IGPT) for operable stage I non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: This single-institutional prospective phase 2 study enrolled patients with operable histologically confirmed stage IA or IB NSCLC (7th edition of UICC). The prescribed dose was 66 Gy relative biological effectiveness equivalents (GyRBE) in 10 fractions for peripheral lesions, or 72...
April 11, 2024: Radiotherapy and Oncology
https://read.qxmd.com/read/38607499/acute-adverse-events-of-ultra-hypofractionated-whole-breast-irradiation-after-breast-conserving-surgery-for-early-breast-cancer-in-japan-an-interim-analysis-of-the-multi-institutional-phase-ii-upbeat-study
#8
JOURNAL ARTICLE
Peter J K Tokuda, Takamasa Mitsuyoshi, Yuka Ono, Takahiro Kishi, Yoshiharu Negoro, Setsuko Okumura, Itaru Ikeda, Takashi Sakamoto, Yumi Kokubo, Ryo Ashida, Toshiyuki Imagumbai, Mikiko Yamashita, Hiroaki Tanabe, Sayaka Takebe, Mariko Tokiwa, Eiji Suzuki, Chikako Yamauchi, Michio Yoshimura, Takashi Mizowaki, Masaki Kokubo
BACKGROUND: The applicability of ultra-hypofractionated (ultra-HF) whole-breast irradiation (WBI) remains unknown in Japanese women. This study aimed to evaluate the safety and efficacy of this approach among Japanese women and report the results of an interim analysis performed to assess acute adverse events (AEs) and determine whether it was safe to continue this study. METHODS: We enrolled Japanese women with invasive breast cancer or ductal carcinoma in situ who had undergone breast-conserving surgery, were aged ≥ 40 years, had pathological stages of Tis-T3 N0-N1, and had negative surgical margins...
April 12, 2024: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://read.qxmd.com/read/38591931/a-phase-i-trial-of-a-methionine-restricted-diet-with-concurrent-radiation-therapy
#9
JOURNAL ARTICLE
Malcolm D Mattes, Igor Koturbash, Calvin N Leung, Sijin Wen, Geraldine M Jacobson
Methionine is an essential amino acid critical for cell growth and survival. Preclinical evidence suggests a methionine restricted diet (MRD) sensitizes cancer to radiation therapy (RT), without significant adverse effects. However, this has never been evaluated in humans. The purpose of this pilot study was to evaluate the safety and feasibility of concurrent MRD with standard-of-care definitive RT in adults with any non-skin cancer malignancy. The MRD extended from 2 wk before RT initiation, through 2 wk beyond RT completion...
April 9, 2024: Nutrition and Cancer
https://read.qxmd.com/read/38591349/cardiovascular-events-among-patients-with-prostate-cancer-treated-with-abiraterone-and-enzalutamide
#10
JOURNAL ARTICLE
Onur Baser, Gabriela Samayoa, Archana Dwivedi, Sara AlSaleh, Burhan Cigdem, Erdi Kizilkaya
BACKGROUND AND PURPOSE: There is growing concern about the adverse metabolic and cardiovascular effects of abiraterone acetate (AA) and enzalutamide (ENZ), two standard hormonal therapies for prostate cancer. We analysed the risk of cardiovascular adverse events among patients treated with AA and ENZ. PATIENTS AND METHODS: We used Kythera Medicare data from January 2019 to June 2023 to identify patients with at least one pharmacy claim for AA or ENZ. The index date was the first prescription claim date...
April 9, 2024: Acta Oncologica
https://read.qxmd.com/read/38591178/survival-outcomes-and-toxicity-profiles-among-patients-with-nonmetastatic-nasopharyngeal-carcinoma-treated-with-intensity-modulated-radiotherapy-imrt-versus-imrt-carbon-ion-radiotherapy-a-propensity-score-matched-analysis
#11
JOURNAL ARTICLE
Yujiao Li, Xiyin Guan, Xing Xing, Chaosu Hu
OBJECTIVES: To compare survival outcomes and toxic effects among patients with newly diagnosed nonmetastatic nasopharyngeal carcinoma (NPC) when treated with intensity-modulated radiotherapy (IMRT) versus IMRT + carbon-ion radiotherapy (CIRT). METHODS: We performed a retrospective propensity score matching analysis (1:1) of patients treated with IMRT and IMRT + CIRT. Descriptive statistics were used to examine the baseline characteristics of the patients...
April 9, 2024: Head & Neck
https://read.qxmd.com/read/38590716/predictors-of-toxicity-in-a-randomized-study-of-consolidation-chemoradiation-versus-observation-after-first-line-chemotherapy-in-advanced-gall-bladder-cancers
#12
JOURNAL ARTICLE
Sushma Agrawal, Anshika Gupta, Vishwas Kapoor, Rahul Rahul, Ashish Singh, Prabhakar Mishra, Rajan Saxena
PURPOSE: Gall bladder cancers (GBC) usually presents in advanced stage. First-line chemotherapy (CT) is the standard of care, and there is no other option for responders than to wait for disease progression. We conducted a randomized study of consolidation chemoradiation (CTRT) versus observation in responders to first line CT (NCT05493956), which showed an improvement in overall survival by 6 months and therefore is practice changing. We are reporting the toxicity and factors predicting toxicity due to CTRT so that it informs appropriate patient selection...
May 2024: Advances in Radiation Oncology
https://read.qxmd.com/read/38589463/androgen-deprivation-alone-versus-combined-with-pelvic-radiation-for-adverse-events-and-quality-of-life-in-clinically-node-positive-prostate-cancer
#13
RANDOMIZED CONTROLLED TRIAL
Tae Hoon Lee, Hongryull Pyo, Gyu Sang Yoo, Jin Hee Kim, Seong Soo Jeon, Seong Il Seo, Byong Chang Jeong, Hwang Gyun Jeon, Hyun Hwan Sung, Minyong Kang, Wan Song, Jae Hoon Chung, Won Park
The COHORT trial was conducted to compare the efficacy of androgen deprivation therapy (ADT) alone versus combined with radiation therapy (ADT + RT) for clinically node-positive prostate cancer. We reported adverse events and quality of life between the two treatment groups. Fifty-nine patients were randomized to receive ADT alone or ADT + RT and analyzed as per-protocol. Patients allocated to the ADT alone arm received ADT for at least 2 years. Patients in the ADT + RT arm received additional pelvic RT...
April 8, 2024: Scientific Reports
https://read.qxmd.com/read/38588920/re-irradiation-for-recurrent-intracranial-meningiomas-analysis-of-clinical-outcomes-and-prognostic-factors
#14
JOURNAL ARTICLE
Isacco Desideri, Ilaria Morelli, Marco Banini, Daniela Greto, Luca Visani, Filippo Nozzoli, Saverio Caini, Alessandro Della Puppa, Lorenzo Livi, Zeno Perini, Emanuele Zivelonghi, Giorgia Bulgarelli, Valentina Pinzi, Pierina Navarria, Elena Clerici, Marta Scorsetti, Anna Maria Ascolese, Mattia Falchetto Osti, Paola Anselmo, Dante Amelio, Giuseppe Minniti, Daniele Scartoni
PURPOSE: Re-irradiation (re-RT) for recurrent intracranial meningiomas is hindered by the limited radiation tolerance of surrounding tissue and the risk of side effects. This study aimed at assessing outcomes, toxicities and prognostic factors in a cohort of patients with recurrent meningiomas re-treated with different RT modalities. MATERIALS AND METHODS: A multi-institutional database from 8 Italian centers including intracranial recurrent meningioma (RM) patients who underwent re-RT with different modalities (SRS, SRT, PT, EBRT) was collected...
April 7, 2024: Radiotherapy and Oncology
https://read.qxmd.com/read/38583495/stereotactic-body-radiotherapy-combined-with-lenvatinib-with-or-without-pd-1-inhibitors-as-initial-treatment-for-unresectable-hepatocellular-carcinoma
#15
JOURNAL ARTICLE
Quan Wang, Xiaoquan Ji, Jing Sun, Aimin Zhang, Jun Jiaa, Teng Zhang, Wengang Li, Xuezhang Duan
PURPOSE: The aim of this study was to compare the clinical benefit and safety of the triple combination of stereotactic body radiotherapy (SBRT), lenvatinib and programmed death 1 (PD-1) inhibitors with the dual combination of SBRT and lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC). METHODS AND MATERIALS: Patients with uHCC who received SBRT in combination with lenvatinib and PD-1 inhibitors or SBRT in combination with lenvatinib alone as first-line treatment from October 2018 to July 2022 were reviewed in this study...
April 5, 2024: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/38583351/a-retrospective-cohort-study-of-neoadjuvant-chemoradiotherapy-combined-with-immune-checkpoint-inhibitors-in-locally-advanced-rectal-cancer
#16
JOURNAL ARTICLE
Zhuo Chen, Zhuoling Zou, Min Qian, Qin Xu, Guojuan Xue, Juan Yang, Tinglan Luo, Lianjie Hu, Bin Wang
INTRODUCTION: This study aimed to investigate the safety and efficacy of neoadjuvant chemoradiotherapy combined with immune checkpoint inhibitors (ICIs) in patients with locally advanced rectal cancer (LARC). Patients diagnosed with LARC and treated with programmed cell death protein-1 (PD-1) inhibitors were recruited. METHODS: Four different treatment strategies were employed in this study: plan A [long-course radiotherapy + PD-1 inhibitor/capecitabine + PD-1 inhibitor/XELOX+ total mesorectal excision (TME)], plan B (long-course radiotherapy + capecitabine + PD-1 inhibitor/XELOX + TME), plan C (short-course radiotherapy + PD-1 inhibitor/XELOX + TME), and plan D (PD-1 inhibitor/XELOX + short-course radiotherapy + TME)...
April 6, 2024: Translational Oncology
https://read.qxmd.com/read/38581480/in-vivo-inhibition-of-neutral-endopeptidase-1-results-in-higher-absorbed-tumor-doses-of-177-lu-lu-pp-f11n-in-humans-the-lumed-phase-0b-study
#17
JOURNAL ARTICLE
Christof Rottenburger, Michael Hentschel, Markus Fürstner, Lisa McDougall, Danijela Kottoros, Felix Kaul, Rosalba Mansi, Melpomeni Fani, A Hans Vija, Roger Schibli, Susanne Geistlich, Martin Behe, Emanuel R Christ, Damian Wild
BACKGROUND: A new generation of radiolabeled minigastrin analogs delivers low radiation doses to kidneys and are considered relatively stable due to less enzymatic degradation. Nevertheless, relatively low tumor radiation doses in patients indicate limited stability in humans. We aimed at evaluating the effect of sacubitril, an inhibitor of the neutral endopeptidase 1, on the stability and absorbed doses to tumors and organs by the cholecystokinin-2 receptor agonist [177 Lu]Lu-PP-F11N in patients...
April 6, 2024: EJNMMI Research
https://read.qxmd.com/read/38577606/pd-1-pd-l1-inhibitor-related-adverse-events-and-their-management-in-breast-cancer
#18
REVIEW
Chuqi Lei, Xiangyi Kong, Yuan Li, Huaiyu Yang, Ke Zhang, Zhongzhao Wang, Hu Chang, Lixue Xuan
As the positive results of multiple clinical trials were released, the Programmed cell death 1 (PD-1) and Programmed cell death ligand 1 (PD-L1) inhibitors emerge as the focus of integrative breast cancer treatment. PD-1/PD-L1 inhibitors are often used as a sequential agent to be combined with other agents such as chemotherapeutic agents, targeted agents, and radiation therapy. As multiple therapies are administered simultaneously or in sequence, they are prone to a variety of adverse effects on patients while achieving efficacy...
2024: Journal of Cancer
https://read.qxmd.com/read/38576855/stereotactic-body-radiation-therapy-in-patients-with-centrally-located-hepatocellular-carcinoma-a-retrospective-single-arm-multi-center-study
#19
JOURNAL ARTICLE
Dan-Xue Zheng, Yi-Xing Chen, Jing Sun, Yong Hu, Ping Yang, Yang Zhang, Xue-Zhang Duan, Zhao-Chong Zeng
Centrally located hepatocellular carcinoma (HCC) is difficult to be radically resected due to its special location close to major hepatic vessels. Thus, we aimed to assess whether stereotactic body radiation therapy (SBRT) can be an effective and safe approach for centrally located HCC. This retrospective study included 172 patients with centrally located HCC who were treated with SBRT. Overall survival (OS) was analyzed as the primary endpoint. Rates of progression-free survival (PFS), local control, intrahepatic relapse, extrahepatic metastasis and toxicities were analyzed as secondary endpoints...
May 2024: Clinical and Translational Radiation Oncology
https://read.qxmd.com/read/38574312/phase-ii-trial-of-cisplatin-gemcitabine-and-intensity-modulated-radiation-therapy-for-locally-advanced-vulvar-squamous-cell-carcinoma-nrg-oncology-gog-study-279
#20
JOURNAL ARTICLE
Neil S Horowitz, Wei Deng, Ivy Peterson, Robert S Mannel, Spencer Thompson, Elizabeth Lokich, Tashanna Myers, Parvis Hanjani, David M O'Malley, Ki Young Chung, David S Miller, Frederick R Ueland, Don S Dizon, Austin Miller, Jyoti S Mayadev, Charles A Leath, Bradley J Monk
PURPOSE: To assess efficacy and toxicity of cisplatin (C) and gemcitabine (G) with intensity-modulated radiation therapy (IMRT) in patients with locally advanced vulvar cancer not amenable to surgery. METHODS: Patients enrolled in a single-arm phase II study. Pretreatment inguinal-femoral nodal assessment was performed. Sixty-four Gy IMRT was prescribed to the vulva, with 50-64 Gy delivered to the groins/low pelvis. Radiation therapy (RT) plans were quality-reviewed pretreatment...
April 4, 2024: Journal of Clinical Oncology
keyword
keyword
160157
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.